Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Kirsten B. Goldberg
FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia With an Isocitrate Dehydrogenase-1 Mutation
Clinical Cancer Research
Cancer Research
Oncology
Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies
Oncologist
Cancer Research
Medicine
Oncology
Related publications
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma
Clinical Cancer Research
Cancer Research
Oncology
Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia
Clinical Hematology International
Mutation Analysis of Isocitrate Dehydrogenase in Acute Lymphoblastic Leukemia
Genetic Testing and Molecular Biomarkers
Medicine
Genetics
A Phase I Study of Carfilzomib for Relapsed or Refractory Acute Myeloid and Acute Lymphoblastic Leukemia
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Salvage Treatment for Refractory or Relapsed Acute Myeloid Leukemia: A 10-Year Single-Center Experience
Clinics
Medicine
Bone Marrow Features in Patients With Acute Myeloid Leukemia Treated With Novel Targeted Isocitrate Dehydrogenase 1/2 Inhibitors
World Journal of Oncology
Cancer Research
Oncology
Low Dose Cytarabine and Cladribine for Treatment of Relapsed or Refractory Acute Myeloid Leukemia: Clinical Experience
Klinicheskaya Onkogematologiya/Clinical Oncohematology
Oncology
Hematology
High Dose Cytarabine Plus Gemtuzumab Ozogamicin for Patients With Relapsed or Refractory Acute Myeloid Leukemia: Cancer and Leukemia Group B Study 19902
Leukemia Research
Cancer Research
Oncology
Hematology
